Germline Pathogenic Variants in Unselected Korean Men with Prostate Cancer

Overview

Journal Investig Clin Urol

Specialty Urology

Date 2022 May 9

PMID 35534218

Authors

Min-Kyung So

Hyun Kyu Ahn

Jungwon Huh

Kwang Hyun Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: Prostate cancer is one of the most heritable cancers and prostate cancer with germline mutations is associated with aggressive features and a poor prognosis. We investigated germline variants in unselected Korean men with prostate cancer.

Materials And Methods: In this study, we prospectively collected buccal swab DNA from 120 unselected Korean men with prostate cancer, and performed massively parallel sequencing. Identified germline variants were interpreted according to the American College of Medical Genetics and Genomics/Association for Molecular Pathology 2015 guidelines.

Results: Of the 120 patients, 30 had regional or metastatic disease and 10, 34, 25, and 21 patients were categorized as having low, intermediate, high, or very high-risk disease, respectively. Of the 88 germline variants, 6 pathologic or likely pathogenic variants were identified in 7 patients (5.8%) with (1.7%), (1.7%), (0.8%), (0.8%), and (0.8%). Of 7 patients, 2 possessed intermediate risk disease that was not included in the recommendation for genetic testing. We identified the Gly132Glu variant, which was different from the Gly84Glu variant of the gene in Western populations.

Conclusions: This study presents the first analysis of germline variants in unselected Korean men with prostate cancer. Our results showed comparable germline prevalence with previous studies and provides evidence for the necessity of genetic testing in Korean men with prostate cancer.

Citing Articles

Clinical relevance of protein-truncating variants of germline DNA repair genes in prostate cancer.

Shao Y, Liao C, Hsu Y, Chiu Y, Lu T, Ou Y BMC Cancer. 2024; 24(1):1319.

PMID: 39455978 PMC: 11520037. DOI: 10.1186/s12885-024-13045-4.

Patterns and Frequency of Pathogenic Germline Variants Among Prostate Cancer Patients Utilizing Multi-Gene Panel Genetic Testing.

Abu Hijlih R, Sharaf B, Salah S, Bani Hani H, Nielsen S, Heald B World J Oncol. 2024; 15(5):801-808.

PMID: 39328335 PMC: 11424115. DOI: 10.14740/wjon1896.

Frequency of Germline and Somatic and Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis.

Valsecchi A, Dionisio R, Panepinto O, Paparo J, Palicelli A, Vignani F Cancers (Basel). 2023; 15(9).

PMID: 37173901 PMC: 10177599. DOI: 10.3390/cancers15092435.

Germline DNA-Repair Genes and HOXB13 Mutations in Korean Men with Metastatic Prostate Cancer: Data from a Large Korean Cohort.

Song S, Kim H, Jung Y, Kook H, Jeon S, Bhak J World J Mens Health. 2023; 41(4):960-968.

PMID: 37118955 PMC: 10523122. DOI: 10.5534/wjmh.220190.

References

Bratt O, Drevin L, Akre O, Garmo H, Stattin P . Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study. J Natl Cancer Inst. 2016; 108(10). DOI: 10.1093/jnci/djw110. View

Lichtenstein P, Holm N, Verkasalo P, Iliadou A, Kaprio J, Koskenvuo M . Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000; 343(2):78-85. DOI: 10.1056/NEJM200007133430201. View

Lek M, Karczewski K, Minikel E, Samocha K, Banks E, Fennell T . Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016; 536(7616):285-91. PMC: 5018207. DOI: 10.1038/nature19057. View

Boyle J, Hahn A, Kapron A, Kohlmann W, Greenberg S, Parnell T . Pathogenic Germline DNA Repair Gene and Mutations in Men With Metastatic Prostate Cancer. JCO Precis Oncol. 2020; 4. PMC: 7446531. DOI: 10.1200/PO.19.00284. View

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-24. PMC: 4544753. DOI: 10.1038/gim.2015.30. View

Kicinski M, Vangronsveld J, Nawrot T . An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PLoS One. 2011; 6(10):e27130. PMC: 3205054. DOI: 10.1371/journal.pone.0027130. View

Wu Y, Yu H, Li S, Wiley K, Zheng S, LaDuca H . Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. Eur Urol Oncol. 2020; 3(2):224-230. DOI: 10.1016/j.euo.2019.12.003. View

Giri V, Knudsen K, Kelly W, Cheng H, Cooney K, Cookson M . Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020; 38(24):2798-2811. PMC: 7430215. DOI: 10.1200/JCO.20.00046. View

. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015; 163(4):1011-25. PMC: 4695400. DOI: 10.1016/j.cell.2015.10.025. View

10.

Mohler J, Antonarakis E, Armstrong A, DAmico A, Davis B, Dorff T . Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(5):479-505. DOI: 10.6004/jnccn.2019.0023. View

11.

Beebe-Dimmer J, Kapron A, Fraser A, Smith K, Cooney K . Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes. J Clin Oncol. 2020; 38(16):1807-1813. PMC: 7255976. DOI: 10.1200/JCO.19.02808. View

12.

Spratt D, Chan T, Waldron L, Speers C, Feng F, Ogunwobi O . Racial/Ethnic Disparities in Genomic Sequencing. JAMA Oncol. 2016; 2(8):1070-4. PMC: 5123755. DOI: 10.1001/jamaoncol.2016.1854. View

13.

Pritchard C, Mateo J, Walsh M, De Sarkar N, Abida W, Beltran H . Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016; 375(5):443-53. PMC: 4986616. DOI: 10.1056/NEJMoa1603144. View

14.

Liede A, Karlan B, Narod S . Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004; 22(4):735-42. DOI: 10.1200/JCO.2004.05.055. View

15.

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

16.

Ewing C, Ray A, Lange E, Zuhlke K, Robbins C, Tembe W . Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012; 366(2):141-9. PMC: 3779870. DOI: 10.1056/NEJMoa1110000. View

17.

Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, OLeary E . Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. JAMA Oncol. 2019; 5(4):523-528. PMC: 6459112. DOI: 10.1001/jamaoncol.2018.6760. View

18.

Wei Y, Wu J, Gu W, Qin X, Dai B, Lin G . Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients. Eur Urol. 2019; 76(3):280-283. DOI: 10.1016/j.eururo.2019.06.004. View

19.

Blackford A, Jackson S . ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. Mol Cell. 2017; 66(6):801-817. DOI: 10.1016/j.molcel.2017.05.015. View

20.

Albright F, Stephenson R, Agarwal N, Teerlink C, Lowrance W, Farnham J . Prostate cancer risk prediction based on complete prostate cancer family history. Prostate. 2014; 75(4):390-8. PMC: 4293302. DOI: 10.1002/pros.22925. View